BRTX Overview

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioRestorative Therapies Inc revenue for the last quarter amounts to 23.17K USD, decreased -7.32

BioRestorative Therapies Inc. EPS for the last quarter amounts to -0.12 USD, decreased -81.25

BioRestorative Therapies Inc (BRTX) has 13 emplpoyees as of May 31 2026.

Today BRTX has the market capitalization of 12.18M USD.